Product Description

Buy Somatropin in Canadian steroids shop. It’s convenient to pay with card.

Our bodybuilding store in Canada provides perfect quality Human Growth Hormone for sale online. Maxtreme Pharma’s Soma-Max-10 is top quality Human Growth Hormone 100IU 10 vials of 10IU (Somatropin) from famous Hormones & Peptides producer.

Our online pharmacy delivers Hormones & Peptides across Canada, so we can ship your order to you fast, safe and discreet no matter where you live: Ontario, Quebec, Alberta, Nova Scotia, New Brunswick, Manitoba, British Columbia, Prince Edward Island, Saskatchewan, Newfoundland and Labrador. Please, use our United States shop for worldwide delivery. We offer reshipping policy for missing, seized or damaged parcels.

We are working as steroid suppliers since March 2009 and have great experience in catering steroids in Canada with full comfort for customers.

Our support department works 24/7 and always ready to answer any questions and solve any problems if such arise suddenly, all packages have tracking codes. We send notification emails for your order’s status change and you can always check current status via our special online service.

Soma-Max-10 is widely known as Somatropin, Somatotropin, Humatrope

In Canada there are alternate names for Soma-Max-10 (Human Growth Hormone): Maxtreme Pharma, Human Growth Hormone, HGH, Human Growth Hormone, HGH, Somatropin 100IU vials of 10IU, Soma-Max-10 100IU vials of 10IU.

All these are different names of the same substance – Human Growth Hormone

Soma-Max – Somatropin For Injection (Lyophilized)

Somatropin (as well as endogenous GH) binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transduction and a host of pharmacodynamic effects. Some of these pharmacodynamic effects are primarily mediated by IGF-1 produced in the liver and also locally (e.g., skeletal growth, protein synthesis), while others are primarily a consequence of the direct effects of somatropin (e.g., lipolysis)

INDICATION

Pediatric Patients

• (somatropin [rDNA origin] injection) is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone (GH).
• [somatropin (rDNA origin) injection] is indicated for the treatment of pediatric patients who have growth failure due to Prader-Willi Syndrome (PWS). The diagnosis of PWS should be confirmed by appropriate genetic testing
• [somatropin (rDNA origin) injection] is indicated for the treatment of growth failure in children born small for gestational age (SGA) who fail to manifest catch-up growth by age 2 years.
• [somatropin (rDNA origin) injection] is indicated for the treatment of growth failure associated with Turner syndrome.
• (somatropin [rDNA origin] injection) is indicated for the treatment of idiopathic short stature (ISS), also called non-growth hormone-deficient short stature, defined by height standard deviation score (SDS) ≤ -2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means.

Adult Patients

• (somatropin [rDNA origin] injection) is indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD) who meet either of the following two criteria:
• Adult Onset (AO): Patients who have GHD, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
• Childhood Onset (CO): Patients who were GH deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes.

Patients who were treated with somatropin for growth hormone deficiency in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin therapy at the reduced dose level recommended for growth hormone deficient adults. Confirmation of the diagnosis of adult growth hormone deficiency in both groups involves an appropriate growth hormone provocative test with two exceptions: (1) patients with multiple other pituitary hormone deficiencies due to organic disease; and (2) patients with congenital/genetic growth hormone deficiency.